We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
![Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies](https://www.ohe.org/wp-content/uploads/2023/01/Cancer_WellcomeCollection_landscape.jpg)
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
![VGD](https://www.ohe.org/wp-content/uploads/2021/02/VGD_0-150x150.png)
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
![Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies](https://www.ohe.org/wp-content/uploads/2020/08/Bridge-150x150.png)